Wave Life Sciences director Heidi L. Wagner exercised options for 7,000 ordinary shares at an exercise price of $5.97 per share on August 11, 2026, and sold the resulting 7,000 shares of common stock at $6.01 per share. The derivative position reported from this option grant was reduced to 0 following the transaction. The company notes these fully vested option exercises and related sale were effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.
Wave Life Sciences, Inc. director Adrian Rawcliffe reported selling 12,700 shares of common stock on August 12, 2026, in an open-market transaction at a reported price of $5.29 per share (weighted average). The sales were effected under a Rule 10b5-1 trading plan adopted on March 6, 2026, and left him with 0 shares of directly held common stock reported in this filing.
Wave Life Sciences, Inc. director Ken Takanashi reported selling 3,864 shares of common stock on August 11, 2026 at a weighted-average price of $6.01 per share, in transactions ranging from $6.01 to $6.03. The sale was made solely to cover taxes from restricted stock units vesting that day, pursuant to a previously adopted Rule 10b5-1 trading plan. After the sale, he directly held 20,079 shares and was reported as indirectly associated with 9,606,408 shares held by SNBL USA, Ltd. and Shin Nippon Biomedical Laboratories, Ltd., for which he disclaims beneficial ownership beyond any pecuniary interest.
Wave Life Sciences, Inc. director Tan Aik Na reported a small open-market sale of 432 shares of common stock on August 11, 2026 at $6.01 per share. According to the disclosure, the shares were sold solely to cover taxes from vesting restricted stock units on the same date, under a previously adopted Rule 10b5-1 Trading Plan. Following this transaction, the director directly holds 24,968 shares of Wave Life Sciences, Inc. common stock.
Wave Life Sciences, Inc. underwent a redomiciliation on August 7, 2026, in which Wave Life Sciences, Inc., a Delaware corporation, became the ultimate parent of the Wave Life Sciences group. Under a Scheme of Arrangement, all ordinary shares of Wave Life Sciences Ltd. were exchanged one-for-one for new shares of Wave Life Sciences, Inc. common stock, par value $0.001 per share, and Wave Life Sciences Ltd. became its wholly owned subsidiary.
RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. report beneficial ownership of 34,314,406 shares of Wave Life Sciences common stock, representing 16.8% of the class. This position consists of 26,975,505 shares held by the Fund, 7,093,656 shares issuable upon exercise of Pre-Funded Warrants, and additional shares and options held by Dr. Kolchinsky for the benefit of RA Capital. The reporting persons generally have shared voting and dispositive power and include recent vesting of 76,200 options at an exercise price of $8.11 and 12,700 restricted stock units on August 11, 2026.
Wave Life Sciences, Inc. filed a post-effective amendment to an existing shelf registration to reflect its redomiciliation from Singapore to Delaware and to adopt the prior Form S-3 under Rule 414 as its own. The amendment covers the resale of up to 7,072,781 shares of common stock by existing selling stockholders. These shares were originally issued by Wave’s Singapore predecessor in various private financings, debt exchanges and its 2015 IPO, and were converted one-for-one into Delaware common stock on August 7, 2026. All shares registered are already outstanding, and the company states it will not receive any proceeds from their sale. As of June 30, 2026, there were 193,277,622 shares of common stock outstanding. The stock trades on the Nasdaq Global Market under the symbol WVE, with a last reported price of $5.74 on August 3, 2026. The filing also describes the new Delaware capital structure, anti-takeover provisions, pre-funded warrants, and existing registration rights for major partners.